Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
1.70
Ask:
2.16
Spread: 0.46 (27.059%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
4th Dec 20084:41 pmRNSSecond Price Monitoring Extn
4th Dec 20084:36 pmRNSPrice Monitoring Extension
7th Nov 200811:05 amRNSChange of NOMAD
31st Oct 200812:10 pmRNSTotal Voting Rights
28th Oct 200812:36 pmRNSBlocklisting Interim Review
22nd Oct 20084:42 pmRNSSecond Price Monitoring Extn
22nd Oct 20084:37 pmRNSPrice Monitoring Extension
20th Oct 20089:38 amRNSHolding(s) in Company
13th Oct 200810:54 amRNSHolding(s) in Company
8th Oct 20082:58 pmPRNChange of Adviser Name
1st Oct 20084:41 pmRNSSecond Price Monitoring Extn
1st Oct 20084:37 pmRNSPrice Monitoring Extension
30th Sep 20087:00 amRNSInterim Results
30th Sep 20087:00 amPRNInterim Results
16th Sep 20084:48 pmRNSSecond Price Monitoring Extn
16th Sep 20084:43 pmRNSPrice Monitoring Extension
5th Aug 20083:37 pmPRNHolding(s) in Company
1st Aug 20084:40 pmRNSSecond Price Monitoring Extn
1st Aug 20084:35 pmRNSPrice Monitoring Extension
31st Jul 20084:13 pmPRNDirector Dealing
30th Jul 20084:40 pmRNSSecond Price Monitoring Extn
30th Jul 20084:35 pmRNSPrice Monitoring Extension
28th Jul 20081:58 pmPRNResult of AGM and Update
2nd Jul 20083:42 pmPRNNotifiable Interest
27th Jun 20089:50 amPRNAnnual Report and Accounts
24th Jun 20087:05 amPRNLoan Agreement
24th Jun 20087:00 amPRNFinal Results
12th Jun 20087:00 amPRNNotice of Allowance for US Patent
20th May 20082:43 pmPRNHolding(s) in Company
8th May 20087:00 amPRNSENS-IT-IV Framework 6 EU Grant Award
25th Apr 20082:30 pmPRNBlocklisting - Interim Review
17th Apr 200810:28 amPRNTotal Voting Rights
1st Apr 20083:20 pmPRNHolding(s) in Company
20th Mar 200812:22 pmPRNTMT Patent Update
13th Mar 20082:55 pmPRNHolding(s) in Company
13th Mar 20082:52 pmPRNHolding(s) in Company
20th Feb 20082:26 pmPRNHolding(s) in Company
18th Feb 200812:25 pmPRNHolding(s) in Company
14th Feb 20085:45 pmPRNHolding(s) in Company
13th Feb 20083:04 pmPRNHolding(s) in Company
5th Feb 20088:36 amPRNStatement re Share Price Movement
23rd Jan 20084:21 pmPRNHolding(s) in Company
18th Jan 20083:53 pmPRNHolding(s) in Company
21st Dec 20077:00 amPRNCurrent Trading
20th Nov 20075:24 pmPRNNotifiable Interests
20th Nov 20075:01 pmPRNNotifiable Interest
19th Nov 20074:33 pmPRNNotifiable Interest (TR-1)
13th Nov 20075:38 pmPRNStatement re Issuance of US Patent
5th Nov 20073:57 pmPRNNotifiable Interest
31st Oct 20077:00 amPRNBlocklisting - Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.